Popular epilepsy drug hits UK market in liquid form

A common treatment for epilepsy has been launched in the UK in liquid form

A common treatment for epilepsy has been introduced to the UK market in liquid form, with the move expected to be of particular benefit to pediatrics.
Tapclob 5mg/5ml and Tapclob 10mg/5ml Oral suspension has been launched in Britain by Martindale Pharma and will be exclusively distributed by Alliance Healthcare Distribution Limited.
It is believed most use of the product will be in children, with one in 100 people in the UK suffering with epilepsy.
This marks the first oral liquid suspension version of clobazam, which is offered by the National Health Service as a prescription treatment for all forms of epilepsy.
Chief executive of Martindale Pharma Richard de Souza said: "We are pleased to have launched the first ever licensed oral liquid formulation of clobazam in the UK."
He added that it will help both prescribers and patients to access a safe and cost-effective oral liquid formulation where necessary.